Dexcom– tag –
-
FDA Approves Firmware Update for Dexcom G5 Mobile Continuous Glucose Monitoring System
FDA.gov USA Overview The U.S. FDA has approved minor design changes to the firmware installed on the transmitter component of the Dexcom G5 Mobile Continuous Glucose Monitoring System. Issued as a Premarket Approval (PMA) supplement, thi... -
Dexcom Secures FDA Authorization for Stelo Glucose Biosensor System, First OTC CGM for Non-Diabetic and Non-Insulin Using Individuals
Devices@FDA (Dexcom) USA Overview Dexcom, Inc. has received FDA authorization for its 'Stelo Glucose Biosensor System,' marking it as the first over-the-counter (OTC) integrated continuous glucose monitor (iCGM) specifically for individu... -
FDA Approves Minor Firmware Design Changes for Dexcom G5 Mobile CGM System Transmitter Component
FDA.gov USA Overview The U.S. FDA has granted a Premarket Approval (PMA) supplement for minor design changes to the firmware installed on the transmitter component of the Dexcom G5 Mobile Continuous Glucose Monitoring System. This approv... -
Five Key Trends in Diabetes Technology for 2026: Longer-Lasting CGMs, OTC Expansion, and Multi-Biomarker Monitoring Lead Innovation
DiabeticSupplieInc.com Unknown Overview Five major trends are shaping diabetes technology in 2026, including longer-lasting continuous glucose monitoring (CGM) sensors like the FDA-cleared Dexcom G7 15-day system, expanded CGM access for... -
FDA Approves Dexcom’s Stelo System as First Over-the-Counter Continuous Glucose Monitor for Children Ages 2-18
RadioWHAT (Facebook) USA Overview The FDA has approved Dexcom's Stelo system as the first over-the-counter (OTC) continuous glucose monitor (CGM) available for children aged 2 to 18 without a prescription. This device provides 15-minute ... -
Abbott Secures Sweeping Injunction Against SiBio’s GS3-R CGM System at Unified Patent Court, Intensifying IP Disputes in Medtech
Facebook USA Overview Abbott Diabetes Care has secured a broad preliminary injunction from the Unified Patent Court (UPC) against SiBio's GS3-R continuous glucose monitoring (CGM) system, effective September 10, 2026. This significant ru... -
FDA Marks New Era in Diabetes Care with First Dual Glucose-Ketone Wearable and OTC Pediatric CGM
FDA News / Health Technology News USA Overview The U.S. FDA has ushered in a new chapter for diabetes technology, authorizing Abbott's Libre Duo as the first wearable device for continuous dual monitoring of glucose and ketones, and clea... -
Dexcom Gains FDA Clearance for G7 15-Day CGM and Smart Basal, Joins TEMPO Pilot Program
Simply Wall St USA Overview Dexcom has secured FDA clearance for its Dexcom G7 15-Day continuous glucose monitoring (CGM) system, extending wear time to 15.5 days for all types of adult diabetes patients. Simultaneously, Dexcom Smart Bas... -
Dexcom’s Investment Outlook Brightens as G7 CGM Gains Expanded Reimbursement for Type 2 Non-Insulin Diabetes Patients
Seeking Alpha USA Overview Dexcom's investment thesis has significantly improved following expanded insurance reimbursement for its G7 continuous glucose monitoring (CGM) systems, now covering a large population of type 2 non-insulin dia... -
Dexcom EVP Kevin R. Sayer to Sell $2.4M in Company Stock by August 20, 2026
SEC Filing - Form 144 / Seeking Alpha USA Overview Dexcom, Inc. Executive Vice President Kevin R. Sayer filed a Rule 144 notice to sell 26,756 shares of common stock, approximately $2.4 million in value, with an anticipated sale date of ...
